A new scale for grading ocular adverse events in oncology trials addresses ambiguities in CTCAE version 5 and includes dose modification recommendations. The scale, implemented in the I-SPY 2 trial, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback